期刊
FASEB JOURNAL
卷 32, 期 10, 页码 5215-5226出版社
WILEY
DOI: 10.1096/fj.201800205R
关键词
epigenetics; fetal programming; obesity; type 2 diabetes; diabetic kidney disease
资金
- University of Technology Sydney
- National Natural Science Foundation of China
- Northern Sydney Local Health District
- University of Sydney through a Sydney Medical School Foundation
Chronic kidney disease (CKD) is a global epidemic, and its major risk factors include obesity and type 2 diabetes. Obesity not only promotes metabolic dysregulation and the development of diabetic kidney disease but also may independently lead to CKD by a variety of mechanisms, including endocrine and metabolic dysfunction, inflammation, oxidative stress, altered renal hemodynamics, and lipotoxicity. Deleterious renal effects of obesity can also be transmitted from one generation to the next, and it is increasingly recognized that offspring of obese mothers are predisposed to CKD. Epigenetic modifications are changes that regulate gene expression without altering the DNA sequence. Of these, DNA methylation is the most studied. Epigenetic imprints, particularly DNA methylation, are laid down during critical periods of fetal development, and they may provide a mechanism by which maternal-fetal transmission of chronic disease occurs. Our current review explores the evidence for the role of DNA methylation in the development of CKD, diabetic kidney disease, diabetes, and obesity. DNA methylation has been implicated in renal fibrosisthe final pathophysiologic pathway in the development of end-stage kidney diseasewhich supports the notion that demethylating agents may play a potential therapeutic role in preventing development and progression of CKD.Larkin, B. P., Glastras, S. J., Chen, H., Pollock, C. A., Saad, S. DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据